Merus N.V. (NASDAQ:MRUS) is a biotechnology company that focuses on developing innovative cancer therapies. The company is known for its bispecific antibody technology, which aims to target and destroy cancer cells more effectively. Merus competes with other biotech firms like Genmab A/S, which is currently involved in a significant transaction with Merus.
On September 29, 2025, Eva Fortea from Wells Fargo set a price target of $97 for MRUS. At that time, the stock was trading at $94.46, showing a potential increase of about 2.69% to reach the target. This price target aligns with the agreed sale price of $97 per share in the ongoing acquisition by Genmab A/S, as highlighted by Halper Sadeh LLC.
Halper Sadeh LLC, an investor rights law firm, is investigating the fairness of the $97 sale price for Merus shareholders. The firm is examining whether Merus and its board of directors have fulfilled their duties to shareholders in this transaction. This scrutiny comes as MRUS stock is currently priced at $94.12, reflecting a significant increase of 36.62% over the past year.
The stock has seen a notable rise of $25.23, with today's trading fluctuating between $94.06 and $94.55. This range marks the highest price for MRUS over the past year, with the lowest being $33.19. The company's market capitalization stands at approximately $7.12 billion, indicating its substantial presence in the biotech sector.
Today's trading volume for MRUS is 14.86 million shares, suggesting strong investor interest. As the investigation by Halper Sadeh LLC continues, stakeholders are closely monitoring the situation to ensure that the sale price reflects the true value of Merus and its innovative cancer therapies.
